SCHEMBL20280922

SCHEMBL20280922

COc1cc2nc(-c3cncc4ccccc34)nc(NCCc3c[nH]c4ccccc34)c2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 12/20 0.58
CYP3A4 P08684 12/20 0.58
CYP2D6 P10635 12/20 0.58
CYP2C19 P33261 12/20 0.58
USP2 O75604 9/20 0.58
CLK4 Q9HAZ1 7/20 0.58
TP53 P04637 7/20 0.58
MAPK1 P28482 4/20 0.58
ALOX15 P16050 4/20 0.58
GBA1 P04062 1/20 0.52
CYP2C9 P11712 9/20 0.52
LMNA P02545 8/20 0.52
MEN1 O00255 8/20 0.52
KMT2A Q03164 8/20 0.52
MAPT P10636 5/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 5/20 0.51
TSHR P16473 5/20 0.51
HSD17B10 Q99714 3/20 0.51
GLA P06280 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20281016 0.85 CYP1A2 (0.67) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20280943 0.85 CYP1A2 (0.61) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20280933 0.84 GBA1 (0.75) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20280944 0.84 CYP1A2 (0.60) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20280951 0.83 CYP1A2 (0.66) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20281071 0.82 HTR1A (0.62) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20280957 0.82 GBA1 (0.56) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20267012 0.81 HTT (0.57) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20280961 0.81 CYP1A2 (0.59) CYP1A2CYP3A4CYP2D6CYP2C19USP2
SCHEMBL20280947 0.80 CYP1A2 (0.56) CYP1A2CYP3A4CYP2D6CYP2C19USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718609-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-08-08 US disclosed
US-11718609-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-08-08 US disclosed
US-20210130338-A1 Heparanase Inhibitors and Use Thereof Beta Therapeutics Pty Ltd (AU) 2021-05-06 US disclosed
US-20200093852-A1 Methods of Treating Ocular Disorders Beta Therapeutics Pty Ltd (AU) 2020-03-26 US disclosed
WO-2018107200-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2018-06-21 WO disclosed
WO-2018107226-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2018-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093852-A1 Methods of Treating Ocular Disorders ALDH1A2, HPSE, RB1 CYP1A2 4837/4885CYP3A4 4824/4885CYP2D6 4841/4885
US-20210130338-A1 Heparanase Inhibitors and Use Thereof HPSE, HEXD, ENGASE CYP1A2 1462/4885CYP3A4 1237/4885CYP2D6 1130/4885
US-11718609-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE CYP1A2 1462/4885CYP3A4 1237/4885CYP2D6 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.